Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia-Reference-Cited by-同舟云学术

Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia

Published:2010-11-18 Issue:1 Volume:152 Page:81-88
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Hernández-Boluda Juan-Carlos,Alvarez-Larrán Alberto,Gómez Montse,Angona Anna,Amat Paula,Bellosillo Beatriz,Martínez-Avilés Luz,Navarro Blanca,Teruel Anabel,Martínez-Ruiz Francisco,Besses Carles

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2010.08430.x/fullpdf

Reference20 articles.

1. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both;Barbui;Seminars in Hematology,2004

2. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group;Barosi;Leukemia,2007

3. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference;Barosi;Blood,2009

4. Hydroxyurea as a cause of drug fever;Braester;Acta Haematologica,2000

5. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study;Campbell;Lancet,2005

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia;2024-08-18

2. The evolving landscape of polycythemia vera therapies;Expert Opinion on Pharmacotherapy;2024-07-23

3. Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature;British Journal of Haematology;2024-06-10

4. Initial Low-Dose Hydroxyurea and Anagrelide Combination in Essential Thrombocythemia: Comparable Response with Lower Toxicity;Journal of Clinical Medicine;2024-05-14

5. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options;Annals of Hematology;2024-03-04